NYSE:NVST - Envista Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $49.80
  • Forecasted Upside: 30.91 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$38.04
▼ -1.05 (-2.69%)

This chart shows the closing price for NVST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Envista Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVST

Analyst Price Target is $49.80
▲ +30.91% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Envista in the last 3 months. The average price target is $49.80, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 30.91% upside from the last price of $38.04.

This chart shows the closing price for NVST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Envista. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/17/2022Stifel NicolausLower Price Target$55.00 ➝ $50.00Medium
6/14/2022Robert W. BairdDowngradeOutperform ➝ Neutral$54.00 ➝ $46.00High
5/5/2022Piper SandlerLower Price Target$50.00 ➝ $49.00High
4/5/2022Robert W. BairdReiterated RatingOutperform ➝ Outperform$54.00Low
4/4/2022Morgan StanleyBoost Price TargetOverweight$52.00 ➝ $56.00Low
2/10/2022Morgan StanleyBoost Price TargetOverweight$48.00 ➝ $52.00High
2/10/2022Piper SandlerBoost Price Target$47.00 ➝ $50.00High
1/31/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$48.00Low
1/7/2022Morgan StanleyBoost Price TargetEqual Weight$42.00 ➝ $45.00Low
10/26/2021Bank of AmericaUpgradeNeutral ➝ Buy$49.00 ➝ $48.00High
8/4/2021Piper SandlerBoost Price TargetNeutral$45.00 ➝ $47.00High
5/7/2021Morgan StanleyBoost Price TargetEqual Weight$42.00 ➝ $46.00Medium
5/6/2021Credit Suisse GroupBoost Price TargetOutperform$49.00 ➝ $55.00High
5/6/2021Piper SandlerBoost Price TargetNeutral$41.00 ➝ $45.00High
3/25/2021Credit Suisse GroupBoost Price TargetOutperform$44.00 ➝ $46.00Low
2/12/2021Morgan StanleyBoost Price TargetEqual Weight$36.00 ➝ $42.00Low
2/11/2021Credit Suisse GroupBoost Price TargetOutperform$41.00 ➝ $44.00Low
2/11/2021Piper SandlerBoost Price TargetNeutral$28.00 ➝ $41.00Low
1/8/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$31.00 ➝ $41.00Low
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$28.00 ➝ $36.00Low
11/25/2020Bank of AmericaBoost Price TargetNeutral$30.00 ➝ $32.00Low
11/2/2020Morgan StanleyBoost Price TargetEqual Weight$24.00 ➝ $28.00Medium
10/30/2020William BlairReiterated RatingOutperformLow
10/30/2020Piper SandlerBoost Price Target$22.00 ➝ $28.00High
10/30/2020JPMorgan Chase & Co.Boost Price TargetOverweight$28.00 ➝ $30.00High
10/30/2020Credit Suisse GroupBoost Price TargetNeutral$25.00 ➝ $31.00Low
10/30/2020JPMorgan Chase & Co.Reiterated RatingOverweight$28.00 ➝ $30.00High
9/15/2020Bank of AmericaBoost Price TargetNeutral$23.00 ➝ $27.00Low
8/3/2020Morgan StanleyBoost Price TargetEqual Weight$18.00 ➝ $24.00Low
7/31/2020Piper SandlerBoost Price TargetNeutral$20.00 ➝ $22.00Medium
7/20/2020Bank of AmericaBoost Price TargetNeutral$21.50 ➝ $23.00Low
6/16/2020Piper SandlerInitiated CoverageNeutral$20.00Medium
6/1/2020JPMorgan Chase & Co.Boost Price TargetOverweight$22.00 ➝ $24.00Low
5/14/2020Morgan StanleyLower Price TargetEqual Weight$20.00 ➝ $18.00Low
5/13/2020Robert W. BairdLower Price TargetOutperform$25.00 ➝ $23.00Low
5/13/2020Bank of AmericaReiterated RatingNeutral$19.50 ➝ $18.00High
5/13/2020Credit Suisse GroupLower Price TargetNeutral$23.00 ➝ $21.00High
3/17/2020JPMorgan Chase & Co.Lower Price TargetOverweight$32.00 ➝ $27.00High
12/17/2019Evercore ISIInitiated CoverageOutperformMedium
10/14/2019William BlairInitiated CoverageOutperformLow
10/14/2019Credit Suisse GroupInitiated CoverageNeutral$30.00Medium
10/14/2019JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Overweight$32.00 ➝ $32.00Medium
10/14/2019Stifel NicolausInitiated CoverageBuy$34.00Medium
10/14/2019Jefferies Financial GroupInitiated CoverageBuy$34.00Medium
10/14/2019The Goldman Sachs GroupInitiated CoverageBuy$33.00Medium
10/14/2019Robert W. BairdInitiated CoverageOutperform$33.00Medium
10/14/2019Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$29.00Medium
10/14/2019Evercore ISIInitiated CoverageOutperform$35.00Medium
10/14/2019Bank of AmericaInitiated CoverageNeutralMedium
(Data available from 7/6/2017 forward)

News Sentiment Rating

-0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/8/2021
  • 8 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/7/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/6/2022
  • 3 very positive mentions
  • 22 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
3/8/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/7/2022
  • 3 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/7/2022
  • 2 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/6/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
7/6/2022

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Envista logo
Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands. This segment also offers software packages, which include DTX Studio Implant for treatment planning of dental implants; TX Studio Lab for prosthetics treatment planning; and DTX Studio Clinic to store and access a various clinical patient images. The company's Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, sensors, software, and other visualization/magnification systems; endodontic systems and related consumables; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Read More

Today's Range

Now: $38.04
Low: $37.98
High: $39.05

50 Day Range

MA: $40.58
Low: $35.59
High: $44.86

52 Week Range

Now: $38.04
Low: $35.24
High: $52.03

Volume

28,209 shs

Average Volume

1,483,832 shs

Market Capitalization

$6.19 billion

P/E Ratio

20.25

Dividend Yield

N/A

Beta

1.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Envista?

The following Wall Street sell-side analysts have issued reports on Envista in the last year: Bank of America Co., Morgan Stanley, Piper Sandler, Robert W. Baird, Stifel Nicolaus, and TheStreet.
View the latest analyst ratings for NVST.

What is the current price target for Envista?

0 Wall Street analysts have set twelve-month price targets for Envista in the last year. Their average twelve-month price target is $49.80, suggesting a possible upside of 30.9%.
View the latest price targets for NVST.

What is the current consensus analyst rating for Envista?

Envista currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVST will outperform the market and that investors should add to their positions of Envista.
View the latest ratings for NVST.

How do I contact Envista's investor relations team?

Envista's physical mailing address is 200 S. KRAEMER BLVD. BUILDING E, BREA CA, 92821. The company's listed phone number is 714-817-7000 and its investor relations email address is [email protected] The official website for Envista is www.envistaco.com. Learn More about contacing Envista investor relations.